572 related articles for article (PubMed ID: 31307049)
1. Management of Patients with Patent Foramen Ovale and Cryptogenic Stroke: An Update.
Abdelghani M; El-Shedoudy SAO; Nassif M; Bouma BJ; de Winter RJ
Cardiology; 2019; 143(1):62-72. PubMed ID: 31307049
[TBL] [Abstract][Full Text] [Related]
2. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
3. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
[TBL] [Abstract][Full Text] [Related]
4. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
5. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
6. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.
Stortecky S; da Costa BR; Mattle HP; Carroll J; Hornung M; Sievert H; Trelle S; Windecker S; Meier B; Jüni P
Eur Heart J; 2015 Jan; 36(2):120-8. PubMed ID: 25112661
[TBL] [Abstract][Full Text] [Related]
7. Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and design.
Khattab AA; Windecker S; Jüni P; Hildick-Smith D; Dudek D; Andersen HR; Ibrahim R; Schuler G; Walton AS; Wahl A; Mattle HP; Meier B
Trials; 2011 Feb; 12():56. PubMed ID: 21356042
[TBL] [Abstract][Full Text] [Related]
8. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
[TBL] [Abstract][Full Text] [Related]
9. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: Meta-Analysis of Randomised Trials.
Wang TKM; Wang MTM; Ruygrok P
Heart Lung Circ; 2019 Apr; 28(4):623-631. PubMed ID: 29602754
[TBL] [Abstract][Full Text] [Related]
10. Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update.
Arfaras-Melainis A; Palaiodimos L; Mojadidi MK
Interv Cardiol Clin; 2019 Oct; 8(4):341-356. PubMed ID: 31445719
[TBL] [Abstract][Full Text] [Related]
11. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
Turc G; Calvet D; Guérin P; Sroussi M; Chatellier G; Mas JL;
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29910193
[TBL] [Abstract][Full Text] [Related]
12. Recurrent Stroke Reduction with Patent Foramen Ovale Closure versus Medical Therapy Based on Patent Foramen Ovale Characteristics: A Meta-Analysis of Randomized Controlled Trials.
Garg A; Thawabi M; Rout A; Sossou C; Cohen M; Kostis JB
Cardiology; 2019; 144(1-2):40-49. PubMed ID: 31574522
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials.
Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E
Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616
[TBL] [Abstract][Full Text] [Related]
14. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials.
Kent DM; Saver JL; Ruthazer R; Furlan AJ; Reisman M; Carroll JD; Smalling RW; Jüni P; Mattle HP; Meier B; Thaler DE
Stroke; 2020 Oct; 51(10):3119-3123. PubMed ID: 32921262
[TBL] [Abstract][Full Text] [Related]
15. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
[TBL] [Abstract][Full Text] [Related]
16. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
[TBL] [Abstract][Full Text] [Related]
17. Updated meta-analysis of closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
Nasir UB; Qureshi WT; Jogu H; Wolfe E; Dutta A; Majeed CN; Tan WA
Cardiovasc Revasc Med; 2019 Mar; 20(3):187-193. PubMed ID: 30905408
[TBL] [Abstract][Full Text] [Related]
18. Cryptogenic stroke and patent foramen ovale.
Thaler DE; Saver JL
Curr Opin Cardiol; 2008 Nov; 23(6):537-44. PubMed ID: 18830067
[TBL] [Abstract][Full Text] [Related]
19. Advances and Ongoing Controversies in Patent Foramen Ovale Closure and Cryptogenic Stroke.
Gonzalez JB; Testai FD
Neurol Clin; 2021 Feb; 39(1):51-69. PubMed ID: 33223089
[TBL] [Abstract][Full Text] [Related]
20. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
